Steatosis and fibrosis in patients with chronic hepatitis C

J Wyatt, H Baker, P Prasad, Y Y Gong, C Millson

Background: Steatosis is present on liver biopsy in approximately 50% of patients with hepatitis C; its association with stage of fibrosis has been reported, but its relation to other fibrosis associated factors is unknown.

Aim: To study the relation between steatosis and other histological features in patients with hepatitis C, and changes in steatosis with time.

Methods: Cross sectional study: 233 routine liver biopsies from 219 patients with hepatitis C; hepatectomy specimens from 65 patients transplanted for hepatitis C cirrhosis. Longitudinal study: 41 patients with two biopsies and 10 patients with three biopsies performed over 2–8 years. Biopsies were scored by the Ishak scheme, and degree of steatosis assessed subjectively. Multivariate analysis was used to study the interaction of fibrosis associated factors. Changes in steatosis over time in individual patients were explored in the longitudinal study.

Results: Steatosis was present in 50% of biopsies. It correlated strongly with fibrosis in non-cirrhotic samples, but declined in cirrhosis, and was unusual in transplant hepatectomy specimens. On multivariate analysis of non-cirrhotic biopsies, steatosis was associated with increasing patient age and remained significantly associated with fibrosis independent of portal inflammation and interface hepatitis. In the longitudinal study, steatosis persisted and increased over time, except in patients developing cirrhosis.

Conclusions: Steatosis is associated with fibrosis independently of necroinflammation, but declines in cirrhosis. It may represent a pathogenic pathway distinct from necroinflammatory activity in the generation of liver fibrosis, and should be included in the assessment of biopsies for clinical and research purposes.

METHOD

Cross sectional study

We studied liver biopsies from patients with chronic hepatitis C who were polymerase chain reaction positive for HCV RNA biopsied at our institution between 1997 and 2001 (group 1). There were 233 adequate liver biopsies (> 1 cm, > 4 portal tracts) from 219 patients: the patients were aged between 17 and 68, with a mean age of 37.9 years; 138 were male and 81 were female. Biopsies were routinely processed; 3 µm thick sections were then stained for reticulin and using haematoxylin and eosin, van Gieson, and periodic acid Schiff diastase. The slides were scored prospectively by one pathologist (JIW) using the Ishak scheme. Fatty change was estimated subjectively and scored as absent (0), or present in < 30% hepatocytes (1+), 30–60% hepatocytes (2+), or > 60% hepatocytes (3+).

Slides from 65 hepatectomy specimens from patients receiving a liver transplant for cirrhosis caused by hepatitis C who were polymerase chain reaction positive for HCV RNA biopsied at our institution between 1997 and 2001 were studied in the same way.

Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; HCV, hepatitis C virus
C were also reviewed, and the presence and extent of steatosis recorded (group 2).

**Longitudinal study**

Fifty one patients who had undergone more than one biopsy (41 with two biopsies and 10 with three biopsies) were identified from departmental records (group 3); these included 14 patients from whom both biopsies were included in group 1, and 37 patients whose previous biopsy was between 1991 and 1997. The time between the first and last biopsies was from one to eight years (mean, 3.33). The following clinical details were collected from these patients’ notes: estimated year and likely route of exposure to hepatitis C, alcohol consumption, weight, hepatitis B status, mean and peak alanine aminotransferase (ALT) concentrations, and details of treatment for hepatitis C.

Slides from these biopsies were retrieved from the departmental file, and the steatosis was reassessed by one pathologist (JIW), blinded to the patient’s identity. The degree of steatosis was scored as 0–3, as above, and the nature of the steatosis (macrovesicular, microvesicular, or mixed) and any features of steatohepatitis—Mallory bodies, ballooning of hepatocytes, and/or zone 3 pericellular collagen deposition—were recorded. In addition, to investigate the importance of mild degrees of steatosis, the biopsies showing grade 1 steatosis were re-scored into three groups: those showing steatosis in <1–2%, 3–10%, and 11–30% of hepatocytes.

**Statistics**

Spearman correlation was used to test the association between age, disease stage, and steatosis. Individual associations between steatosis and inflammatory grade, and the comparison of steatosis in paired biopsies was by the \( \chi^2 \) test or Fisher’s exact test. Multivariate analysis for the factors associated with steatosis and fibrosis was done using the General Linear Model. Statistical package Stata7.0 (Stata Corporation, College Station, Texas, USA) was used for all the data analysis.

**RESULTS**

Steatosis was present in 117 of 233 (50.2%) biopsies from group 1 patients, whereas fibrosis was found in 148 of 233 (63.5%). There was a significant association between steatosis and inflammatory grade, and the comparison of steatosis in paired biopsies was by the \( \chi^2 \) test or Fisher’s exact test. Multivariate analysis for the factors associated with steatosis and fibrosis was done using the General Linear Model. Statistical package Stata7.0 (Stata Corporation, College Station, Texas, USA) was used for all the data analysis.

**Table 1**

<table>
<thead>
<tr>
<th>Steatosis score</th>
<th>Stage of fibrosis on biopsy</th>
<th>Total biopsies</th>
<th>Transplant hepatectomy</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>54 33 14 3 2 4 7 117 51</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>27 28 12 10 0 5 4 26 8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>4 5 6 1 4 5 6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>1 1 0 0 1 1 1 5 0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>86 66 31 19 4 12 15 233 65</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

at the time of transplantation than in needle biopsies from patients found to have cirrhotic livers on biopsy (\( p = 0.03 \)).

Because steatosis showed a positive association with stage of fibrosis in biopsies from non-cirrhotic livers, but declined in patients with cirrhosis, we excluded biopsies from patients with cirrhosis in our statistical analysis of factors associated with fibrosis and steatosis.

Steatosis and fibrosis in patients without cirrhosis

By univariate analysis, steatosis showed a significant association with increasing patient age (\( p < 0.0001 \)). It was seen more frequently in men, but this association was not significant (\( p = 0.067 \)). In addition to the association between steatosis and stage of fibrosis (\( p < 0.0001 \)), we found a significant association between steatosis and interface hepatitis (\( p = 0.005 \)) and portal inflammation (\( p = 0.001 \)), but not with lobular activity (\( p = 0.374 \)).

Fibrosis was significantly more common in men than in women (\( p = 0.005 \)) and there was a significant association between stage of fibrosis and increasing patient age (\( p < 0.0001 \)). All three components of the necroinflammatory score showed a significant association with fibrosis (interface hepatitis, \( p < 0.0001 \); portal inflammation, \( p < 0.0001 \); and lobular necroinflammation, \( p = 0.0004 \)).

![Figure 1](http://jcp.bmj.com/ "Proportion of biopsies with steatosis according to stage of fibrosis in 233 liver biopsies and 65 hepatectomy specimens from patients with hepatitis C.")
Multivariate analysis
We found that the association between steatosis and fibrosis remained significant in the multivariate model when age, sex, and necroinflammatory activity were considered (p = 0.005). In single factor correlation analysis, we found that both steatosis and fibrosis were significantly associated with age (p < 0.0001 for both, Spearman test). However, in the multivariate model, the correlation between steatosis and age still existed (p < 0.0001), whereas the correlation between fibrosis and age disappeared when steatosis and the necroinflammatory activity factors were taken into account (p = 0.159); fig 2 shows the statistical associations between these factors.

The factors that were significantly associated with fibrosis in the multivariate model were steatosis (p = 0.005), portal inflammation, and interface hepatitis. Once fibrosis was added into the multivariate model the associations of portal inflammation and interface hepatitis with steatosis disappeared, indicating that the univariate association with steatosis is because each factor is separately linked to fibrosis. The univariate associations of male sex (p = 0.005) and lobular necroinflammation (p = 0.0004) with fibrosis did not remain significant in the multivariate model.

Patients with follow up biopsies
The presence or absence of steatosis was concordant between first and last biopsies in 38 of the 51 patients with follow up biopsies (group 3). There was a strong positive association between steatosis score in the first biopsy and second biopsy (p < 0.001). Steatosis was both macrovesicular and microvesicular in most biopsies, and none showed convincing evidence of steatohepatitis.

Table 2 shows the degree of steatosis in first and final biopsies for group 3 patients. The degree of steatosis increased between the first and the last biopsy in 18 patients, decreased in eight patients, and was unchanged in 25 patients. In most patients acquiring steatosis, this was very mild (affecting 1–2% hepatocytes in six of nine patients), whereas this degree of steatosis persisted or increased in five of seven patients who had 1–2% steatosis on initial biopsy, suggesting that steatosis is initially very mild and increases gradually over time.

Twenty two patients were treated for hepatitis C in the multivariate model: 13 patients (eight type 1, one type 2, eight type 3). The year of viral infection was determined in 17 cases (eight type 1, one type 2, eight type 3). The year of viral acquisition was known for 18 patients, and could be estimated in 17 patients; history of intravenous drug use and other risk factors was recorded in all cases, as were mean and peak serum ALT concentrations.

Comparison with clinical variables showed that there was a trend for steatosis to be associated with higher weight (p = 0.049), but not alcohol intake or viral genotype (p = 0.5 for both). However, alcohol consumption was significantly associated with the stage of fibrosis (p = 0.029).

Steatosis in the second biopsy correlated with the mean ALT value between biopsies (p = 0.029), and there was a consistent trend for a correlation between mean ALT and necroinflammatory scores (p = 0.039, 0.07, and 0.08 for portal, interface, and lobular inflammation, respectively). Neither steatosis nor fibrosis showed a significant correlation with estimated time since the acquisition of hepatitis C; in addition, the rate of fibrosis was not related to the presence of steatosis.

DISCUSSION
In our study, steatosis was present in 50% of liver biopsies from patients with hepatitis C. The presence of steatosis was significantly correlated with patient age and stage of fibrosis; and multivariate analysis of non-cirrhotic biopsies indicated that steatosis and necroinflammation were independent factors in the development of fibrosis. Our follow up study of 51 patients showed that steatosis, once present, persists and tends to increase with time; a recent study of 96 untreated patients identified worsening steatosis as the only factor independently associated with fibrosis progression on multivariate analysis.18

Whereas steatosis correlated with stage of fibrosis in non-cirrhotic biopsies, the development of cirrhosis was associated with a decrease in steatosis; there was less steatosis in biopsies from patients with cirrhosis than in those with bridging fibrosis (stage 3–5) on biopsy, and less in patients with advanced cirrhosis coming to transplant than in those in whom cirrhosis was diagnosed on routine biopsy for the assessment of chronic hepatitis C. The regression of steatosis in patients with established cirrhosis has been reported previously in patients with hepatitis C19 and non-alcoholic steatohepatitis.38 Possible explanations for this include the poor nutritional state of patients with cirrhosis, alterations of intrahepatic circulation and portal–systemic shunting, or the capillarisation of sinusoids.11 In hepatitis C, examination of our transplant hepatectomy specimens showed that steatosis when present affected most hepatocytes in occasional nodules. In view of the suggestion that steatosis is a cytopathic effect of HCV,11 an alternative explanation could be that the absence of steatosis in late cirrhosis reflects selection for the regeneration of hepatocytes resistant to this cytopathic effect.

“Whereas steatosis correlated with stage of fibrosis in non-cirrhotic biopsies, the development of cirrhosis was associated with a decrease in steatosis”

We found a highly significant association between steatosis and stage of fibrosis in non-cirrhotic biopsies, as has previously been demonstrated in several.7 8 15-17 but not all,
Steatosis in hepatitis C is strongly associated with increased fibrosis in non-cirrhotic liver biopsies, it increases in prevalence with age, and once present tends to persist. Steatosis is associated with fibrosis independently of necroinflammatory activity, but declines in patients with cirrhosis. Steatosis probably reflects an interaction of viral and host factors important in the generation of fibrosis in the liver, so that those with steatosis in early stage disease may be at increased risk of progressive fibrosis. To understand its role in the pathogenesis of hepatitis C, the assessment of steatosis should be included in the evaluation of biopsies for clinical and research purposes.

### Table 2: Degree of steatosis in first and last biopsy for 51 patients in group 3

<table>
<thead>
<tr>
<th>Steatosis in first biopsy</th>
<th>None</th>
<th>1–2%</th>
<th>3–10%</th>
<th>11–30%</th>
<th>&gt;30%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steatosis in second biopsy</td>
<td>None</td>
<td>15</td>
<td>6</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>1–2%</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>3–10%</td>
<td>1</td>
<td>1</td>
<td>4</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>11–30%</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>&gt;30%</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>3</td>
</tr>
</tbody>
</table>

### References


### Authors’ affiliations

J Wyatt, H Baker, P Prasad, Department of Histopathology, St James’s Hospital, Leeds LS9 7TF, UK

C Millson, Department of Hepatology, St James’s Hospital

Y Y Gong, Molecular Epidemiology Unit, University of Leeds School of Medicine, Leeds, UK

### Take home messages

- Steatosis is strongly associated with increased fibrosis in non-cirrhotic liver biopsies, it increases in prevalence with age, and once present tends to persist.
- Steatosis is associated with fibrosis independently of necroinflammatory activity, but declines in patients with cirrhosis.
- Steatosis probably reflects an interaction of viral and host factors important in the generation of fibrosis in the liver, so that those with steatosis in early stage disease may be at increased risk of progressive fibrosis.
- To understand its role in the pathogenesis of hepatitis C, the assessment of steatosis should be included in the evaluation of biopsies for clinical and research purposes.
Pancolonic dye aids surveillance for adenomas

Patients with chronic ulcerative colitis (UC) have a better chance that precancerous lesions heralding adenomas will be apparent during surveillance if their colon is sprayed with contrast dye, an endoscopic study has found. Using this method routinely would be more efficient, requiring fewer biopsies and less histological screening.

Spraying with indigo carmine dye showed a strong trend towards detection: precancerous lesions (2–6 mm diameter) were detected in seven patients versus only two with standard endoscopic examination in the same 100 patients. A total of 2904 non-targeted biopsy specimens disclosed no cases of dysplasia; 43 targeted specimens—in the vicinity of any irregularity in colonic epithelium—showed two precancerous lesions on histological analysis, but it was the 114 specimens in 55 patients taken after dye spraying that yielded a further seven instances of precancerous lesions (in five patients), all thought to be adenomas.

Routine biopsy rates in the UK can be as low as 10 or fewer per patient or well below the 30–40 rate recommended by the American Society for Gastrointestinal Endoscopy, so the increased sensitivity of endoscopic surveillance with the dye is a clear benefit to UK patients, say the authors.

Patients with chronic UC for eight or more years underwent endoscopic surveillance and biopsy for precancerous lesions: once according to the American guidelines with non-targeted biopsies, plus targeted biopsies near visually suspicious areas of colon, then again, after 1% indigo carmine pancolonic spray in a back to back procedure, when additional visible abnormalities were biopsied.